Latest News
EU approves Sanofi and Regeneron's Dupixent for young children with chronic spontaneous urticaria
13 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced on Monday that they have received European Commission approval for Dupixent (du...
Haisco Pharmaceutical signs global pain‑drug licensing deal with AbbVie
...
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
13 April 2026 - Canadian pharmaceutical company Apotex Inc announced on Friday that its US subsidiary Apotex Corp has received the first US Food and Drug Administration (FDA) tentative approval for its Abbreviated New Drug Application (ANDA) for Sema...
Lupin's Dapagliflozin Tablets launched in US market
13 April 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Friday the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States.Lupin's Abbreviated New Drug Application for Dapaglifl...
AnBogen Therapeutics to present Imofinostat (ABT-301) breakthroughs at AACR 2026
13 April 2026 - AnBogen Therapeutics, a Taiwan-based, clinical-stage biotechnology company focused on precision oncology, announced on Monday that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for p...